Percutaneous coronary intervention in patients with diabetes: current concepts and future directions - PubMed (original) (raw)
Review
Percutaneous coronary intervention in patients with diabetes: current concepts and future directions
Ehrin J Armstrong et al. J Diabetes Sci Technol. 2014 May.
Abstract
Patients with diabetes and coronary artery disease represent a challenging and growing subset of the population. Although surgical revascularization is the preferred treatment for patients with diabetes and multivessel coronary artery disease with stable angina, a significant proportion of diabetic patients undergo percutaneous revascularization due to comorbidities, presence of single-vessel disease, or presentation with myocardial infarction. The development of drug-eluting stents has significantly improved the results of percutaneous revascularization among diabetic patients, but a number of challenges remain, including higher rates of restenosis and stent thrombosis among diabetic patients. With current technologies, the outcomes of diabetic patients treated with noninsulin agents have approached that of nondiabetic patients. In comparison, patients with diabetes who require insulin therapy represent a high-risk cohort with increased rates of target vessel failure after coronary revascularization. The development of bioresorbable stents and new drug elution systems may provide additional future benefit among patients with diabetes undergoing percutaneous coronary artery revascularization.
Keywords: coronary artery disease; diabetes; drug-eluting stents.
© 2014 Diabetes Technology Society.
Conflict of interest statement
Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JHR is a consultant for Medtronic and Boston Scientific.
Figures
Figure 1.
Differential outcomes after percutaneous coronary intervention (PCI) among patients with and without diabetes treated with everolimus-eluting or paclitaxel-eluting stents. (A) Among patients without diabetes, the rates of major adverse cardiovascular events were significantly lower for those treated with everolimus-eluting stents (EES) compared to paclitaxel-eluting stents (PES). However, patients with DM had similar outcomes regardless of the drug-eluting stent type. (B) Among patients without diabetes, EES were also associated with significantly decreased rates of target lesion revascularization (TLR). In comparison, there was no relationship between stent type and TLR among patients with DM. (Reproduced, with permission, from Stone et al.)
Figure 2.
Association of insulin-treated diabetes with outcomes after percutaneous coronary intervention with Resolute zotarolimus-eluting stents (R-ZES). Patient-level data were pooled from 5130 patients receiving R-ZES in 5 clinical trials (Resolute FIM, Resolute All Comers, Resolute International, Resolute US and Resolute Japan). Patients without diabetes (non-DM) and those with diabetes treated with agents other than insulin (non-ITDM) had similar rates of target lesion failure (TLF; defined as a composite of cardiac death, target vessel myocardial infarction, and ischemia-driven target vessel revascularization). Patients with diabetes who required treatment with insulin (ITDM) had significantly increased rates of adverse events. (Reproduced, with permission, from Silber et al.)
Similar articles
- Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial.
Konigstein M, Ben-Yehuda O, Smits PC, Love MP, Banai S, Perlman GY, Golomb M, Ozan MO, Liu M, Leon MB, Stone GW, Kandzari DE. Konigstein M, et al. JACC Cardiovasc Interv. 2018 Dec 24;11(24):2467-2476. doi: 10.1016/j.jcin.2018.09.033. JACC Cardiovasc Interv. 2018. PMID: 30573057 Clinical Trial. - Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
Silber S, Serruys PW, Leon MB, Meredith IT, Windecker S, Neumann FJ, Belardi J, Widimsky P, Massaro J, Novack V, Yeung AC, Saito S, Mauri L. Silber S, et al. JACC Cardiovasc Interv. 2013 Apr;6(4):357-68. doi: 10.1016/j.jcin.2012.11.006. Epub 2013 Mar 20. JACC Cardiovasc Interv. 2013. PMID: 23523454 - Clinical outcomes of contemporary drug-eluting stents in patients with and without diabetes mellitus: Multigroup propensity-score analysis using data from stent-specific, multicenter, prospective registries.
Kwon O, Lee JB, Ahn JM, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park DW, Park SJ; IRIS-DES Registry Investigators. Kwon O, et al. Catheter Cardiovasc Interv. 2020 Aug;96(2):243-252. doi: 10.1002/ccd.28462. Epub 2019 Sep 3. Catheter Cardiovasc Interv. 2020. PMID: 31478593 - Comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease: a meta-analysis.
Li X, Kong M, Jiang D, Dong A. Li X, et al. Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):347-54. doi: 10.1093/icvts/ivt509. Epub 2013 Dec 16. Interact Cardiovasc Thorac Surg. 2014. PMID: 24345688 Free PMC article. Review. - Comparison of drug-eluting and bare-metal stents in patients with diabetes undergoing primary percutaneous coronary intervention: what is the evidence?
Gollop ND, Henderson DB, Flather MD. Gollop ND, et al. Interact Cardiovasc Thorac Surg. 2014 Jan;18(1):112-6. doi: 10.1093/icvts/ivt454. Epub 2013 Oct 20. Interact Cardiovasc Thorac Surg. 2014. PMID: 24144807 Free PMC article. Review.
Cited by
- Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus.
Thomas A, Kereiakes DJ, Baumbach A, Windecker S, Pietras C, Dressler O, Issever MO, Curtis M, Bertolet B, Zidar JP, Smits PC, Jiménez Díaz VA, McLaurin B, Cequier Á, Takahashi A, Cannon LA, Amoroso G, Kakuta T, Saito S, Leon MB, Lansky AJ. Thomas A, et al. J Soc Cardiovasc Angiogr Interv. 2022 Apr 11;1(2):100033. doi: 10.1016/j.jscai.2022.100033. eCollection 2022 Mar-Apr. J Soc Cardiovasc Angiogr Interv. 2022. PMID: 39132558 Free PMC article. - Patients With Diabetes at High Bleeding Risk With 1-Month Dual Antiplatelet Therapy: Onyx ONE Clear Results.
Kedhi E, Windecker S, Latib A, Kirtane AJ, Kandzari D, Mehran R, Price MJ, Abizaid A, Simon DI, Zaman A, Fabbiocchini F, Tie C, van 't Hof A, de la Torre Hernandez JM, Hammett CJ, McLaurin B, Potluri S, Smith T, Waksman R, Ragosta M, Parke M, Lung TH, Stone GW. Kedhi E, et al. J Soc Cardiovasc Angiogr Interv. 2022 Aug 25;1(5):100441. doi: 10.1016/j.jscai.2022.100441. eCollection 2022 Sep-Oct. J Soc Cardiovasc Angiogr Interv. 2022. PMID: 39131461 Free PMC article. - Fractional flow reserve measurements and long-term mortality-results from the FLORIDA study.
Boeckling F, Stähli BE, Rudolph T, Lutz M, Schatz AS, Vogelmann T, Stueve M, West NEJ, Boone E, Erbay A, Leistner DM. Boeckling F, et al. Front Cardiovasc Med. 2024 Feb 9;11:1337941. doi: 10.3389/fcvm.2024.1337941. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38404721 Free PMC article. - Spatial Reorganization of Liquid Crystalline Domains of Red Blood Cells in Type 2 Diabetic Patients with Peripheral Artery Disease.
Bianchetti G, Rizzo GE, Serantoni C, Abeltino A, Rizzi A, Tartaglione L, Caputo S, Flex A, De Spirito M, Pitocco D, Maulucci G. Bianchetti G, et al. Int J Mol Sci. 2022 Sep 22;23(19):11126. doi: 10.3390/ijms231911126. Int J Mol Sci. 2022. PMID: 36232429 Free PMC article. - Diabetes and restenosis.
Wilson S, Mone P, Kansakar U, Jankauskas SS, Donkor K, Adebayo A, Varzideh F, Eacobacci M, Gambardella J, Lombardi A, Santulli G. Wilson S, et al. Cardiovasc Diabetol. 2022 Feb 14;21(1):23. doi: 10.1186/s12933-022-01460-5. Cardiovasc Diabetol. 2022. PMID: 35164744 Free PMC article. Review.
References
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053. - PubMed
- Gersh BJ, Sliwa K, Mayosi BM, Yusuf S. The epidemic of cardiovascular disease in the developing world: global implications. Eur Heart J. 2010;31:642-648. - PubMed
- Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140-2144. - PubMed
- Lankisch M, Futh R, Gulker H, et al. Screening for undiagnosed diabetes in patients with acute myocardial infarction. Clin Res Cardiol. 2008;97:753-759. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical